|Industry||Pharmaceuticals, Drugs & Healthcare|
|Headquarters||Mumbai, Maharashtra, India|
Yogesh Agrawal, Managing Director.Rajesh Agrawal, Joint Managing Director
|Products||Branded Generic Formulations / Medicines|
|Revenue||₹1,705 crore (US$250 million) (2015–2016)|
Number of employees
Ajanta Pharma (Mauritius) Ltd, Ajanta Pharma Philippines Inc., Ajanta Pharma USA Inc.,Ajanta Pharma Nigeria Ltd.
Ajanta Pharma Limited (APL) (BSE: 532331 | NSE: AJANTPHARM) is an Indian multinational, engaged in development, manufacturing and marketing of pharmaceutical formulations. It has presence in India, USA and about 30 Emerging countries including Africa, Philippines, Rest of Asia, Middle East and CIS. Established in 1973, Ajanta Pharma has rich experience of over 4 decades in pharma industry with impeccable record of quality. The company has always been pioneering in its efforts to service the ailing mankind. It has unique advantage of launching innovative R&D products in the market ahead of competition, many of them being first of its kind.
With steady and substantial investment in R&D, use of latest platform technology and developing niche and complex formulation, company is confident of reinforcing its exclusive positioning in the markets it operates in. At Ajanta Pharma, consistent performance and sustained profitable growth defines its capacity to deliver superior operating and financial performance over the long term. With its mission of 'Serving Global Health Care Needs Worldwide', a team of 6000+ Ajantaites with different nationalities ensure providing quality medicines to the patients in different parts of the world.
Key Markets & Business
Ajanta Pharma’s strategy of right things at right time focusses on identifying opportunities and capitalising them ahead of others. In doing so, it identifies unmet medical needs across therapies in different markets, develop customised products suitable to satisfy these unmet needs ahead of competition and launch it through its own front end team. This conclusively enables it to grow above the industry average.
Company chooses its areas of geographic presence and therapeutic segments with a clear understanding of opportunity and its ability to place speciality differentiated and complex products in that market. Company has over 1,400 products registered currently in various countries and equal number of products are under approval.
In India, company is a branded generic player with clear vision to remain focused on few high growth specialty therapies of Ophthalmology, Dermatology, Cardiology and Pain Management, where it has built a leadership position. Company’s inherently focus on innovation to provide better products to consumers has led it to penetrate the market with most 1st to market launches in speciality product portfolios. Company has been consistently growing faster than the industry and has been improving its ranking over the years. Currently company is ranked 33rd in Indian Pharmaceutical market as per IMS MAT June 2016. Within Therapeutic Segments Company is ranked 5th in Ophthalmology, 13th in Dermatology, 20th in Cardiology and 44th in Pain management as per IMS MAT June 2016.
Ajanta Pharma has a clear vision on which markets in wants to operate in. It has diligently pursued this strategy to build a better balanced, substantially de-risked geographic mix in the emerging markets.
Company follows a country specific and product specific model and exports products to over 30 countries in Asia and Africa. In these markets, company serves a wide range of therapeutic segments of Anti Malaria, Cardio, GI, Antibiotic, Derma, Anti Histamine, Multivitamin, Gynaec, Pain Management, etc. What is unique is, all these markets are serviced by company’s own dedicated front end team, which gives it an edge in the market place.
Company has recently stepped up its presence in the USA with a select product portfolio, which includes niche and complex technology products, deriving competitive advantage in the market. Currently company has 8 products launched in the market and many more awaiting launches. Company has a firm product pipeline under development for the USA market and expect to file about 8-12 ANDAs every year with US FDA.
Ajanta Pharma operates 6 state-of-the-art manufacturing facilities; 5 within India and 1 in Mauritius. In India, 4 facilities manufacture finished formulations, including recently commissioned Dahej plant which is getting ready to obtain US FDA approval. Another 1 plant manufactures Active Pharmaceutical Ingredients (APIs) primarily for captive consumption.
The company is in the process of setting up 1 more formulations manufacturing facility at Guwahati in Assam for domestic and emerging markets and is on course to be operationalized by March 2017.
Regular investments in capacity signals company’s confidence in growth and opportunities ahead.
Quality is institutionalised at company’s manufacturing facilities through sophisticated mechanisms and automation, training programmes and enabling infrastructure support. Quality is the primary focus from product development to delivery. That is what has enabled one of its manufacturing facility to get approved by leading pharmaceutical stringent regulatory authorities such as the USFDA and World Health Organisation.
Innovation is at the heart of Ajanta Pharma and fundamental to the implementation of its strategy of helping patients’ access quality medicines. It focuses on speciality formulations, identifying the right segments, products and markets.
R&D is a key differentiator in Ajanta’s growth, strategic positioning, and vital in maintaining and strengthening leading market position. Over the years, company has built significant expertise in various platform technologies in the finished formulations of various dosage forms. Recently, it has added dedicated process chemistry R&D to develop niche, limited competition and complex API’s to enable corresponding formulation development and capitalize the opportunities.
Continuous investment in the product pipeline has enabled Ajanta Pharma to lead first-to-market product launches in key markets. Its continuous R&D investment has helped the company to introduce around 20 new products in India every year.
Its highly-skilled research team is dedicated to develop innovative products using cutting edge technologies and platforms for positively improving health as well as overall well-being of patients.
- Ajanta Pharma, "One of the Giants of Tomorrow" - Fortune India’
- Managing Director & Joint Managing Director conferred with TIME India 'Young Maker of the Year' award by the hands of Hon. Prime Minister Narendra Modi, during ‘Make In India Week’
- Ajanta Pharma Ltd Listed in 'Forbes India - Super 50 Companies'
- Managing Director & Joint Managing Director's interview on Zee Business
- Ajanta Pharma Ltd |Company Profile